Company Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.
The company was incorporated in 2012 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2012 |
| IPO Date | Apr 29, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Dr. Brian Lian Ph.D. |
Contact Details
Address: 9920 Pacific Heights Blvd, Suite 350 San Diego, California 92121 United States | |
| Phone | 858-704-4660 |
| Website | vikingtherapeutics.com |
Stock Details
| Ticker Symbol | VKTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001607678 |
| CUSIP Number | 92686J106 |
| ISIN Number | US92686J1060 |
| Employer ID | 46-1073877 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Brian Lian Ph.D. | President, Chief Executive Officer and Director |
| Gregory S. Zante | Chief Financial Officer |
| Marianne Mancini | Chief Operating Officer |
| Michael Morneau | Vice President of Finance and Administration |
| Dr. Geoffrey E. Barker Ph.D. | Senior Vice President of Pharmaceutical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 4, 2024 | 8-K | Current Report |
| May 23, 2024 | 8-K | Current Report |
| May 23, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 23, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 23, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 23, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 23, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 23, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 23, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 23, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |